Page 32 - Practice Guidelines News Today

RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2- metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus endocrine

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

/PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted its annual NCCN Patient Advocacy Summit....

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 - Helsinn Group ("Helsinn"), a fully integrated global

More than 1.4 million men were diagnosed with prostate cancer in 2020 globally, but the molecular characteristics of the disease remain unexplored for the majority of patients around the world.

National Comprehensive Cancer Network and the Latin American and Caribbean Society of Medical Oncology collaborate to address policy and practice solutions to increase equitable access for breast

HUDDERSFIELD, UK / ACCESSWIRE / November 16, 2022 / Paxman Coolers Limited, MedTech company and manufacturer of the Paxman Scalp Cooling System - cryotherapy technology to mitigate the risk of chemotherapy-induced

The National Comprehensive Cancer Network- a non-profit alliance of leading cancer centers across the United States-;is launching a collaborative project with the Latin American and Caribbean Society of Medical Oncology in Buenos Aires, Argentina, today.

/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a non-profit alliance of leading cancer centers across the United States—is launching a...

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in The Lancet Haematology, which summarizes the Phase 1...